SLDB - Solid Biosciences Inc.

Insider Sale by Cumbo Alexander (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Cumbo Alexander, serving as Pres, CEO at Solid Biosciences Inc. (SLDB), sold 16,644 shares at $5.82 per share, for a total transaction value of $96,923.00. Following this transaction, Cumbo Alexander now holds 235,405 shares of SLDB.

This sale represents a 7.00% decrease in Cumbo Alexander's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 18, 2026, meaning the disclosure happened on the same day as the trade.

Solid Biosciences Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cumbo Alexander

Pres, CEO

Alexander (Bo) Cumbo is the President and Chief Executive Officer of Solid Biosciences Inc. (SLDB), a gene therapy company, a position he has held since December 2022 with a tenure of approximately 3.2 years as of early 2026[[1]](https://fintool.com/app/research/companies/VOR/people/alexander-cumbo)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/management). In this role, he leads the company, earning total yearly compensation of $4.87 million (12.5% salary, 87.5% bonuses including stock and options) and directly owning 0.35% of shares worth about $1.77 million[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/management). Recently, as a corporate insider, he executed automatic sales of shares to cover tax withholding on vested restricted and performance stock units, including 80,258 shares on February 2, 2026, at $6.4369 per share, and 48,913 shares on February 4, 2026, at $6.4419 per share, retaining 222,018 shares post-transaction[[3]](https://www.stocktitan.net/sec-filings/SLDB/form-4-solid-biosciences-inc-insider-trading-activity-3cc9b9a0a734.html)[[4]](https://longbridge.com/en/news/274580194)[[5]](https://www.investing.com/news/insider-trading-news/solid-biosciences-ceo-cumbo-sells-315092-in-stock-93CH-4492255). Cumbo brings extensive biotech experience, having served as the founding CEO of AavantiBio (backed by Bain, Perceptive, and RA Capital) and nearly eight years as Executive Vice President and Chief Commercial Officer at Sarepta Therapeutics, where he launched multiple rare disease therapies and built global commercial operations[[1]](https://fintool.com/app/research/companies/VOR/people/alexander-cumbo). He holds a B.S. in Laboratory Technology from Auburn University and currently serves on the boards of Vor Biopharma (joined July 16, 2025), Verve Therapeutics, and Climb Bio, adding expertise in commercialization, company building, and gene therapy scaling[[1]](https://fintool.com/app/research/companies/VOR/people/alexander-cumbo)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/management).

View full insider profile →

Trade Price

$5.82

Quantity

16,644

Total Value

$96,923.00

Shares Owned

235,405

Trade Date

Wednesday, February 18, 2026

4 days ago

SEC Filing Date

Wednesday, February 18, 2026

HEALTHCAREBIOTECHNOLOGY

About Solid Biosciences Inc.

Company Overview

No company information available
View news mentioning SLDB

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4102151

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime